Price
$1.15 K
Decreased by -0.95%
Dollar volume (20D)
499.47 M
ADR%
1.86
Earnings report date
Oct 31, 2024
Shares float
103.45 M
Shares short
2.10 M [2.03%]
Shares outstanding
108.42 M
Market cap
128.36 B
Beta
0.12
Price/earnings
30.86
20D range
1.11 K 1.21 K
50D range
1.03 K 1.21 K
200D range
792.57 1.21 K

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 1, 24 11.56
Increased by +12.89%
10.61
Increased by +8.95%
May 2, 24 9.55
Decreased by -5.35%
10.09
Decreased by -5.35%
Feb 2, 24 11.86
Decreased by -5.57%
10.73
Increased by +10.53%
Nov 2, 23 11.59
Increased by +4.04%
10.72
Increased by +8.12%
Aug 3, 23 10.24
Increased by +4.81%
9.84
Increased by +4.07%
May 4, 23 10.09
Increased by +12.99%
9.56
Increased by +5.54%
Feb 3, 23 12.56
Decreased by -41.09%
10.03
Increased by +25.22%
Nov 3, 22 11.14
Decreased by -22.48%
9.48
Increased by +17.51%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 3.15 B
Decreased by -0.54%
722.00 M
Decreased by -11.71%
Increased by +22.96%
Decreased by -11.23%
Dec 31, 23 3.43 B
Increased by +0.58%
1.16 B
Decreased by -3.13%
Increased by +33.77%
Decreased by -3.69%
Sep 30, 23 3.36 B
Increased by +14.53%
1.01 B
Decreased by -23.40%
Increased by +29.97%
Decreased by -33.12%
Jun 30, 23 3.16 B
Increased by +10.53%
968.40 M
Increased by +13.65%
Increased by +30.66%
Increased by +2.82%
Mar 31, 23 3.16 B
Increased by +6.64%
817.80 M
Decreased by -15.99%
Increased by +25.86%
Decreased by -21.23%
Dec 31, 22 3.41 B
Decreased by -31.05%
1.20 B
Decreased by -46.29%
Increased by +35.06%
Decreased by -22.11%
Sep 30, 22 2.94 B
Decreased by -14.96%
1.32 B
Decreased by -19.39%
Increased by +44.81%
Decreased by -5.21%
Jun 30, 22 2.86 B
Decreased by -44.40%
852.10 M
Decreased by -72.50%
Increased by +29.82%
Decreased by -50.55%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY